New therapeutic approaches to combat arterial thrombosis

Molecular Interventions

Volumn 11, Issue 2, 2011, Pages 111-123

  Choi, Jaehwa ^a   Kermode, John C ^b  

^a SOUTHWESTERN OKLAHOMA STATE UNIVERSITY   (United States)

^b PHILADELPHIA COLLEGE OF OSTEOPATHIC MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

3A,4,4A,5,6,7,8,8A,9,9A DECAHYDRO N [4 [2 [5 (3 FLUOROPHENYL) 2 PYRIDYL]VINYL] 3 METHYL 1 OXO 3H BENZO[F]ISOBENZOFURAN 7 YL]CARBAMIC ACID ETHYL ESTER; ABCIXIMAB; ACETYLSALICYLIC ACID; ACETYLSALICYLIC ACID 3 (NITROXYMETHYL)PHENYL ESTER; ANTITHROMBOCYTIC AGENT; ATOPAXAR; BX 667; CANGRELOR; CILOSTAZOL; CLOPIDOGREL; COLLAGEN; CYTOCHROME P450; DIPYRIDAMOLE; E 5555; ELINOGREL; EPTIFIBATIDE; FIBRINOGEN RECEPTOR ANTAGONIST; GLIBENCLAMIDE; NEW DRUG; PRASUGREL; PROTEINASE ACTIVATED RECEPTOR 1; PURINERGIC P2Y12 RECEPTOR; SARPOGRELATE; SEROTONIN 2A RECEPTOR; TERUTROBAN; THROMBOXANE A2; THROMBOXANE A2 RECEPTOR; TICAGRELOR; TICLOPIDINE; TIROFIBAN; UNCLASSIFIED DRUG; UNINDEXED DRUG; VORAPAXAR;

APLASTIC ANEMIA; ARTERY THROMBOSIS; ATHEROSCLEROTIC PLAQUE; BLEEDING; BRAIN HEMORRHAGE; BRAIN ISCHEMIA; CARDIOVASCULAR DISEASE; CLINICAL TRIAL (TOPIC); DRUG EFFICACY; DRUG MECHANISM; DRUG METABOLISM; DRUG POTENTIATION; DRUG STRUCTURE; DRUG TARGETING; DYSPNEA; GASTROINTESTINAL SYMPTOM; HEART INFARCTION; HEART VENTRICLE FUNCTION; HUMAN; INTERMITTENT CLAUDICATION; LOW DRUG DOSE; NEUTROPENIA; NONHUMAN; PARACRINE SIGNALING; PATIENT COMPLIANCE; PERIPHERAL VASCULAR DISEASE; RESTENOSIS; REVIEW; SIDE EFFECT; STENT THROMBOSIS; STROKE; STRUCTURE ACTIVITY RELATION; THROMBOCYTE ACTIVATION; THROMBOCYTE AGGREGATION; THROMBOSIS;

ANIMALS; ARTERIES; BLOOD PLATELETS; HUMANS; MOLECULAR TARGETED THERAPY; PLATELET AGGREGATION INHIBITORS; SIGNAL TRANSDUCTION; THROMBOSIS;

EID: 79955683495     PISSN: 15340384     EISSN: 15432548     Source Type: Journal    
DOI: 10.1124/mi.11.2.9     Document Type: Review

References (99)

1. Meadows TA and Bhatt DL (2007) Clinical aspects of platelet inhibitors and thrombus formation. Circ Res 100:1261-1275. This detailed review is an excellent introduction to the role of platelets in atherothrombosis and to the anti-platelet drugs that are in current use as well as many that are in development. (Pubitemid 46742917)
2. Jackson SP, Nesbitt WS, and Westein E (2009) Dynamics of platelet thrombus formation. J Thromb Haemost 7 (Suppl 1):17-20.
3. Ruggeri ZM (2009) Platelet adhesion under flow. Microcirculation 16:58-83. This review includes a very thorough description of the mechanisms responsible for platelet adhesion to the vascular subendothelium after rupture of atherosclerotic plaque.
4. (Pubitemid 351549284)
5. Linden MD and Jackson DE (2010) Platelets: Pleiotropic roles in atherogenesis and atherothrombosis. Int J Biochem Cell Biol 42:1762-1766.
6. Rivera J, Lozano ML, Navarro-Núñez L, and Vicente V (2009) Platelet receptors and signaling in the dynamics of thrombus formation. Haematologica 94:700-711.
7. Gachet C (2008) P2 receptors, platelet function and pharmacological implications. Thromb Haemost 99:466-472. (Pubitemid 351549282)
8. Jennings LK (2009) Mechanisms of platelet activation: Need for new strategies to protect against platelet-mediated atherothrombosis. Thromb Haemost 102:248-257.
9. Bhatt DL (2010) Acute coronary syndrome update for hospitalists. J Hosp Med 5 (Suppl 4):S15-S21.
10. de Lau LM, den Hertog HM, van den Herik EG, and Koudstaal PJ (2009) Predicting and preventing stroke after transient ischemic attack. Expert Rev Neurother 9:1159-1170.
11. Kolandaivelu K and Bhatt DL (2011) Antiplatelet therapy in coronary heart disease prevention. Cardiol Clin 29:71-85.
12. Spinler SA and Rees C (2009) Review of prasugrel for the secondary prevention of atherothrombosis. J Manag Care Pharm 15:383-395.
13. Cohen M (2009) Oral antiplatelet therapy for acute and chronic management of NSTE ACS: Residual ischemic risk and opportunities for improvement. Cardiovasc Drugs Ther 23:489-499.
14. Jackson SP and Schoenwaelder SM (2003) Antiplatelet therapy: In search of the 'magic bullet'. Nat Rev Drug Discov 2:775-789. (Pubitemid 37361810)
15. Campbell CL, Smyth S, Montalescot G, and Steinhubl SR (2007) Aspirin dose for the prevention of cardiovascular disease: A systematic review. J Am Med Assoc 297:2018-2024. (Pubitemid 46740354)
16. Kawabe J-I, Ushikubi F, and Hasebe N (2011) Prostacyclin in vascular diseases: Recent insights and future perspectives. Circ J 74:836-843.
17. Antithrombotic Trialists' (ATT) Collaboration (2009) Aspirin in the primary and secondary prevention of vascular disease: Collaborative metaanalysis of individual participant data from randomised trials. Lancet 373:1849-1860. This recent meta-analysis of data from six primary prevention trials and 16 secondary prevention trials confirms the effectiveness of anti-platelet therapy with aspirin at suppressing atherothrombosis.
18. Cattaneo M (2011) Resistance to antiplatelet drugs: Molecular mechanisms and laboratory detection. J Thromb Haemost 5 (Suppl 1):230- 237. The author of this recent review provides a useful discussion of the concept, frequency, and clinical consequence of resistance to the anti-platelet drugs aspirin and clopidogrel. (Pubitemid 46958838)
19. Snoep JD, Hovens MMC, Eikenboom JCJ, van der Bom JG, and Huisman MV (2007) Association of laboratory-defined aspirin resistance with a higher risk of recurrent cardiovascular events: A systematic review and meta-analysis. Arch Intern Med 167:1593-1599. (Pubitemid 47280339)
20. CAPRIE Steering Committee (1996) A randomised, blinded, trial of clopidogrel versus aspirin in patients at risk of ischaemic events (CAPRIE). Lancet 348:1329-1339. The CAPRIE clinical trial reported in this study was the first to establish the effectiveness of clopidogrel as a single-drug therapy for atherothrombosis.
21. Angiolillo DJ, Ueno M, and Goto S (2010) Basic principles of platelet biology and clinical implications. Circ J 74:597-607.
22. Mehta SR, Yusuf S, Peters RJG, Bertrand ME, Lewis BS, Natarajan MK, Malmberg K, Rupprecht H-J, Zhao F, Chrolavicius S, et al., for the Clopidogrel in Unstable angina to prevent Recurrent Events trial (CURE) Investigators (2001) Effects of pretreatment with clopidogrel and aspirin followed by long-term therapy in patients undergoing percutaneous coronary intervention: The PCI-CURE study. Lancet 358:527-533. The PCI-CURE trial reported in this article provided the basis for dual anti-platelet therapy as a means to prevent atherothrombotic events in the context of percutaneous coronary intervention. (Pubitemid 32772726)
23. Serebruany VL, Steinhubl SR, Berger PB, Malinin AI, Bhatt DL, and Topol EJ (2005) Variability in platelet responsiveness to clopidogrel among 544 individuals. J Am Coll Cardiol 45:246-251. (Pubitemid 40094733)
24. Snoep JD, Hovens MMC, Eikenboom JCJ, van der Bom JG, Jukema JW, and Huisman MV (2007) Clopidogrel nonresponsiveness in patients undergoing percutaneous coronary intervention with stenting: A systematic review and meta-analysis. Am Heart J 154:221-231. (Pubitemid 47069129)
25. Hulot J-S, Bura A, Villard E, Azizi M, Remones V, Goyenvalle C, Aiach M, Lechat P, and Gaussem P (2006) Cytochrome P450 2C19 loss-offunction polymorphism is a major determinant of clopidogrel responsiveness in healthy subjects. Blood 108:2244-2247. (Pubitemid 44497506)
26. Beitelshees AL, Horenstein RB, Vesely MR, Mehra MR, and Shuldiner AR (2011) Pharmacogenetics and clopidogrel response in patients undergoing percutaneous coronary interventions. Clin Pharmacol Ther 89:455-459.
27. Mega JL, Simon T, Collet J-P, Anderson JL, Antman EM, Bliden K, Cannon CP, Danchin N, Giusti B, Gurbel P, et al. (2010) Reducedfunction CYP2C19 genotype and risk of adverse clinical outcomes among patients treated with clopidogrel predominantly for PCI: A metaanalysis. J Am Med Assoc 304:1821-1830. This recent meta-analysis of data from nine studies establishes the role of cytochrome P450 2C19 as an important determinant of the clinically relevant responsiveness of patients to clopidogrel therapy.
28. Shuldiner AR, O'Connell JR, Bliden K, Gandhi A, Ryan K, Horenstein RB, Damcott CM, Pakyz R, Tantry US, Gibson Q, et al. (2009) Association of cytochrome P450 2C19 genotype with the antiplatelet effect and clinical efficacy of clopidogrel therapy. J Am Med Assoc 302:849-858.
29. Mega JL, Close SL, Wiviott SD, Shen L, Walker JR, Simon T, Antman EM, Braunwald E, and Sabatine MS (2010) Genetic variants in ABCB1 and CYP2C19 and cardiovascular outcomes after treatment with clopidogrel and prasugrel in the TRITON-TIMI 38 trial: A pharmacogenetic analysis. Lancet 376:1312-1319.
30. Michelson AD (2010) Antiplatelet therapies for the treatment of cardiovascular disease. Nat Rev Drug Discov 9:154-169.
31. Ibbotson T, McGavin JK, and Goa KL (2003) Abciximab: An updated review of its therapeutic use in patients with ischaemic heart disease undergoing percutaneous coronary revascularisation. Drugs 63:1121-1163. (Pubitemid 36700391)
32. Hagemeyer CE and Peter K (2010) Targeting the platelet integrin GPIIb/ IIIa. Curr Pharm Des 16:4119-4133.
33. O'Donnell MJ, Hankey GJ, and Eikelboom JW (2008) Antiplatelet therapy for secondary prevention of noncardioembolic stroke: A critical review. Stroke 39:1638-1646.
34. Weber R and Diener H-C (2010) Controversies and future perspectives of antiplatelet therapy in secondary stroke prevention. J Cell Mol Med 14:2371-2380.
35. Aktas B, Utz A, Hoenig-Liedl P, Walter U, and Geiger J (2003) Dipyridamole enhances NO/cGMP-mediated vasodilator-stimulated phosphoprotein phosphorylation and signaling in human platelets: In vitro and in vivo/ex vivo studies. Stroke 34:764-769. (Pubitemid 36307408)
36. Sugidachi A, Ogawa T, Kurihara A, Hagihara K, Jakubowski JA, Hashimoto M, Niitsu Y, and Asai F (2007) The greater in vivo antiplatelet effects of prasugrel as compared to clopidogrel reflect more efficient generation of its active metabolite with similar antiplatelet activity to that of clopidogrel's active metabolite. J Thromb Haemost 5:1545-1551. (Pubitemid 46965386)
37. Small DS, Farid NA, Payne CD, Konkoy CS, Jakubowski JA, Winters KJ, and Salazar DE (2010) Effect of intrinsic and extrinsic factors on the clinical pharmacokinetics and pharmacodynamics of prasugrel. Clin Pharmacokinet 49:777-798.
38. Franchini M and Mannucci PM (2009) New antiplatelet agents: Why they are needed. Eur J Intern Med 20:733-738.
39. Jernberg T, Payne CD, Winters KJ, Darstein C, Brandt JT, Jakubowski JA, Naganuma H, Siegbahn A, and Wallentin L (2006) Prasugrel achieves greater inhibition of platelet aggregation and a lower rate of non-responders compared with clopidogrel in aspirin-treated patients with stable coronary artery disease. Eur Heart J 27:1166-1173.
40. Wiviott SD, Antman EM, Gibson CM, Montalescot G, Riesmeyer J, Weerakkody G, Winters KJ, Warmke JW, McCabe CH, and Braunwald E, for the TRITON-TIMI 38 Investigators (2006) Evaluation of prasugrel compared with clopidogrel in patients with acute coronary syndromes: Design and rationale for the TRial to assess Improvement in Therapeutic Outcomes by optimizing platelet InhibitioN with prasugrel Thrombolysis In Myocardial Infarction 38 (TRITON-TIMI 38). Am Heart J 152:627-635. (Pubitemid 44396884)
41. Siddique A, Butt M, Shantsila E, and Lip GYH (2009) New antiplatelet drugs: Beyond aspirin and clopidogrel. Int J Clin Pract 63:776-789.
42. Wiviott SD, Braunwald E, McCabe CH, Montalescot G, Ruzyllo W, Gottlieb S, Neumann F-J, Ardissino D, De Servi S, Murphy SA, et al., for the TRITON-TIMI 38 Investigators (2007) Prasugrel versus clopidogrel in patients with acute coronary syndromes. N Engl J Med 357:2001-2015. This article reports the primary findings of the TRITON-TIMI 38 clinical trial, which established the greater efficacy of prasugrel than clopidogrel at suppressing atherothrombosis. (Pubitemid 350106708)
43. Wiviott SD, Braunwald E, McCabe CH, Horvath I, Keltai M, Herrman J-PR, Van de Werf F, Downey WE, Scirica BM, Murphy SA, et al., for the TRITON-TIMI 38 Investigators (2008) Intensive oral antiplatelet therapy for reduction of ischaemic events including stent thrombosis in patients with acute coronary syndromes treated with percutaneous coronary intervention and stenting in the TRITON-TIMI 38 trial: A subanalysis of a randomised trial. Lancet 371:1353-1363. Follow-up data analysis in this article describes the remarkable reduction in stent thrombosis in patients receiving prasugrel in the TRITON-TIMI 38 clinical trial.
44. Wiviott SD, Braunwald E, Angiolillo DJ, Meisel S, Dalby AJ, Verheugt FWA, Goodman SG, Corbalan R, Purdy DA, Murphy SA, et al., for the TRITON-TIMI 38 Investigators (2008) Greater clinical benefit of more intensive oral antiplatelet therapy with prasugrel in patients with diabetes mellitus in the trial to assess improvement in therapeutic outcomes by optimizing platelet inhibition with prasugrel - thrombolysis in myocardial infarction 38. Circulation 118:1626-1636. This report establishes the particular effectiveness of prasugrel at suppressing atherothrombosis in patients with diabetes mellitus; it is also based on further analysis of data from the TRITON-TIMI 38 trial.
45. Floyd JS and Serebruany VL (2010) Prasugrel as a potential cancer promoter: Review of the unpublished data. Arch Intern Med 170:1078-1080.
46. Paikin JS, Eikelboom JW, Cairns JA, and Hirsh J (2010) New antithrombotic agents - insights from clinical trials. Nat Rev Cardiol 7:498-509.
47. Marczewski MM, Postula M, and Kosior D (2010) Novel antiplatelet agents in the prevention of cardiovascular complications - focus on ticagrelor. Vasc Health Risk Manag 6:419-429.
48. Abergel E and Nikolsky E (2010) Ticagrelor: An investigational oral antiplatelet treatment for reduction of major adverse cardiac events in patients with acute coronary syndrome. Vasc Health Risk Manag 6:963-977.
49. Husted S, Emanuelsson H, Heptinstall S, Sandset PM, Wickens M, and Peters G (2006) Pharmacodynamics, pharmacokinetics, and safety of the oral reversible P2Y12 antagonist AZD6140 with aspirin in patients with atherosclerosis: A double-blind comparison to clopidogrel with aspirin. Eur Heart J 27:1038-1047.
50. James S, Åkerblom A, Cannon CP, Emanuelsson H, Husted S, Katus H, Skene A, Steg PG, Storey RF, Harrington R, et al. (2009) Comparison of ticagrelor, the first reversible oral P2Y12 receptor antagonist, with clopidogrel in patients with acute coronary syndromes: Rationale, design and baseline characteristics of the PLATelet inhibition and patient Outcomes (PLATO) trial. Am Heart J 157:599-605.
51. Wallentin L, Becker RC, Budaj A, Cannon CP, Emanuelsson H, Held C, Horrow J, Husted S, James S, Katus H, et al., for the PLATO Investigators (2009) Ticagrelor versus clopidogrel in patients with acute coronary syndromes. N Engl J Med 361:1045-1057. This article reports the findings of the PLATO clinical trial, which established the effectiveness of ticagrelor as an anti-platelet agent in patients with acute coronary syndrome and led to its approval by the European Commission.
52. Gaglia MA and Waksman R (2011) Overview of the 2010 Food and Drug Administration Cardiovascular and Renal Drugs Advisory Committee meeting regarding ticagrelor. Circulation 123:451-456.
53. Storey RF, Oldroyd KG, and Wilcox RG (2001) Open multicentre study of the P2T receptor antagonist AR-C69931MX assessing safety, tolerability and activity in patients with acute coronary syndromes. Thromb Haemost 85:401-407. (Pubitemid 32233008)
54. Harrington RA, Stone GW, McNulty S, White HD, Lincoff AM, Gibson CM, Pollack CV, Montalescot G, Mahaffey KW, Kleiman NS, et al. (2011) Platelet inhibition with cangrelor in patients undergoing PCI. N Engl J Med 361:2318-2329.
55. Bhatt DL, Lincoff AM, Gibson CM, Stone GW, McNulty S, Montalescot G, Kleiman NS, Goodman SG, White HD, Mahaffey KW, et al., for the CHAMPION PLATFORM Investigators (2011) Intravenous platelet blockade with cangrelor during PCI. N Engl J Med 361:2330-2341.
56. Ueno M, Rao SV, and Angiolillo DJ (2011) Elinogrel: Pharmacological principles, preclinical and early phase clinical testing. Future Cardiol 6:445-453.
57. Leonardi S, Rao SV, Harrington RA, Bhatt DL, Gibson CM, Roe MT, Kochman J, Huber K, Zeymer U, Madan M, et al. (2010) Rationale and design of the randomized, double-blind trial testing INtraveNous and Oral administration of elinogrel, a selective and reversible P2Y12-receptor inhibitor, versus clopidogrel to eVAluate Tolerability and Efficacy in nonurgent Percutaneous Coronary Interventions patients (INNOVATE-PCI). Am Heart J 160:65-72.
58. Bryant J, Post JM, Alexander S, Wang Y-X, Kent L, Schirm S, Tseng J-L, Subramanyam B, Buckman B, Islam I, et al. (2008) Novel P2Y12 adenosine diphosphate receptor antagonists for inhibition of platelet aggregation (I): In vitro effects on platelets. Thromb Res 122:523-532.
59. Post JM, Alexander S, Wang Y-X, Vincelette J, Vergona R, Kent L, Bryant J, Sullivan ME, Dole WP, Morser J, et al. (2008) Novel P2Y12 adenosine diphosphate receptor antagonists for inhibition of platelet aggregation (II): Pharmacodynamic and pharmacokinetic characterization. Thromb Res 122:533-540.
60. Uchiyama S, Demaerschalk BM, Goto S, Shinohara Y, Gotoh F, Stone WM, Money SR, and Kwon SU (2009) Stroke prevention by cilostazol in patients with atherothrombosis: Meta-analysis of placebo-controlled randomized trials. J Stroke Cerebrovasc Dis 18:482-490.
61. Biondi-Zoccai GGL, Lotrionte M, Anselmino M, Moretti C, Agostoni P, Testa L, Abbate A, Cosgrave J, Laudito A, Trevi GP, et al. (2008) Systematic review and meta-analysis of randomized clinical trials appraising the impact of cilostazol after percutaneous coronary intervention. Am Heart J 155:1081-1089.
62. Gresele P and Momi S (2006) Pharmacologic profile and therapeutic potential of NCX 4016, a nitric oxide-releasing aspirin, for cardiovascular disorders. Cardiovasc Drug Rev 24:148-168. (Pubitemid 46696922)
63. Antoniades C, Tousoulis D, and Stefanadis C (2007) Nitric oxidereleasing aspirin: Will it say NO to atherothrombosis? Int J Cardiol 118:170-172. (Pubitemid 46601645)
64. Momi S, Pitchford SC, Alberti PF, Minuz P, Del Soldato P, and Gresele P (2005) Nitroaspirin plus clopidogrel versus aspirin plus clopidogrel against platelet thromboembolism and intimal thickening in mice. Thromb Haemost 93:535-543. (Pubitemid 40394142)
65. Gresele P, Migliacci R, Procacci A, De Monte P, and Bonizzoni E (2007) Prevention by NCX 4016, a nitric oxide-donating aspirin, but not by aspirin, of the acute endothelial dysfunction induced by exercise in patients with intermittent claudication. Thromb Haemost 97:444-450. (Pubitemid 46437807)
66. Ting HJ and Khasawneh FT (2010) Platelet function and isoprostane biology: Should isoprostanes be the newest member of the orphan ligand family? J Biomed Sci 17:24.
67. The RAPT Investigators (1994) Randomized trial of ridogrel, a combined thromboxane A2 synthase inhibitor and thromboxane A2/prostaglandin endoperoxide receptor antagonist, versus aspirin as adjunct to thrombolysis in patients with acute myocardial infarction: The Ridogrel versus Aspirin Patency Trial (RAPT). Circulation 89:588-595.
68. Hong T-T, Huang J, Driscoll E, and Lucchesi BR (2006) Preclinical evaluation of S18886 in an experimental model of coronary arterial thrombosis. J Cardiovasc Pharmacol 48:239-248.
69. Vilahur G, Casani L, and Badimon L (2007) A thromboxane A2/prostaglandin H2 receptor antagonist (S18886) shows high antithrombotic efficacy in an experimental model of stent-induced thrombosis. Thromb Haemost 98:662-669. (Pubitemid 47412894)
70. Belhassen L, Pelle G, Dubois-Rande J-L, and Adnot S (2003) Improved endothelial function by the thromboxane A2 receptor antagonist S 18886 in patients with coronary artery disease treated with aspirin. J Am Coll Cardiol 41:1198-1204. (Pubitemid 36384909)
71. Bal dit Sollier C, Crassard I, Simoneau G, Bergmann JF, Bousser MG, and Drouet L (2009) Effect of the thromboxane prostaglandin receptor antagonist terutroban on arterial thrombogenesis after repeated administration in patients treated for the prevention of ischemic stroke. Cerebrovasc Dis 28:505-513.
72. Bousser MG, Amarenco P, Chamorro A, Fisher M, Ford I, Fox K, Hennerici MG, Mattle HP, Rothwell PM, and PERFORM Study Investigators (2009) Rationale and design of a randomized, double-blind, parallel-group study of terutroban 30 mg/day versus aspirin 100 mg/ day in stroke patients: The prevention of cerebrovascular and cardiovascular events of ischemic origin with terutroban in patients with a history of ischemic stroke or transient ischemic attack (PERFORM) study. Cerebrovasc Dis 27:509-518.
73. Ting HJ, Murray WJ, and Khasawneh FT (2010) Repurposing an old drug for a new use: Glybenclamide exerts antiplatelet activity by interacting with the thromboxane A2 receptor. Acta Pharmacol Sin 31:150-159.
74. Angiolillo DJ, Capodanno D, and Goto S (2010) Platelet thrombin receptor antagonism and atherothrombosis. Eur Heart J 31:17-28.
75. Lang NN, Guomundsdóttir IJ, and Newby DE (2010) Vascular PAR-1: Activity and antagonism. Cardiovasc Ther. Epub ahead of print, doi: 10.1111/j.1755-5922.2010.00140.x
76. Sugunaraj JP, Mehta V, Kalra A, Sukhija R, and Palaniswamy C (2011) Protease-activated receptor-1 antagonists: Focus on SCH 530348. Am J Ther. Epub ahead of print, doi: 10.1097/MJT.0b013e3181ff7c16
77. Becker RC, Moliterno DJ, Jennings LK, Pieper KS, Pei J, Niederman A, Ziada KM, Berman G, Strony J, Joseph D, et al., for the TRA-PCI Investigators (2009) Safety and tolerability of SCH 530348 in patients undergoing non-urgent percutaneous coronary intervention: A randomised, double-blind, placebo-controlled phase II study. Lancet 373:919-928. The phase 2 trial reported in this article established the safety of vorapaxar as a potential new approach for anti-platelet therapy in patients undergoing percutaneous coronary intervention.
78. Serebruany VL, Kogushi M, Dastros-Pitei D, Flather M, and Bhatt DL (2009) The in-vitro effects of E5555, a protease-activated receptor (PAR)-1 antagonist, on platelet biomarkers in healthy volunteers and patients with coronary artery disease. Thromb Haemost 102:111-119.
79. Goto S, Ogawa H, Takeuchi M, Flather MD, and Bhatt DL, on behalf of the J-LANCELOT (Japanese-Lesson from Antagonizing the Cellular Effect of Thrombin) Investigators (2010) Double-blind, placebo-controlled phase II studies of the protease-activated receptor 1 antagonist E5555 (atopaxar) in Japanese patients with acute coronary syndrome or highrisk coronary artery disease. Eur Heart J 31:2601-2613.
80. Nagatomo T, Rashid M, Muntasir HA, and Komiyama T (2004) Functions of 5-HT2A receptor and its antagonists in the cardiovascular system. Pharmacol Ther 104:59-81. (Pubitemid 39410563)
81. Norgren L, Jawien A, Mátyás L, Rieger H, Arita K, and the European MCI-9042 Study Group (2006) Sarpogrelate, a 5-HT2A receptor antagonist in intermittent claudication: A phase II European study. Vasc Med 11:75-83. (Pubitemid 44130375)
82. Shinohara Y, Nishimaru K, Sawada T, Terashi A, Handa S, Hirai S, Hayashi K, Tohgi H, Fukuuchi Y, Uchiyama S, et al., for the S-ACCESS Study Group (2008) Sarpogrelate-aspirin comparative clinical study for efficacy and safety in secondary prevention of cerebral infarction (S-ACCESS): A randomized, double-blind, aspirin-controlled trial. Stroke 39:1827-1833.
83. Shinohara Y and Nishimaru K, for the S-ACCESS Study Group (2009) Sarpogrelate versus aspirin in secondary prevention of cerebral infarction: Differential efficacy in diabetes? Subgroup analysis from S-ACCESS. Stroke 40:2862-2865. The subgroup analysis of data from the S-ACCESS trial reported in this article suggests that sarpogrelate might be more effective than aspirin for secondary prevention of stroke.
84. Adams JW, Ramirez J, Shi Y, Thomsen W, Frazer J, Morgan M, Edwards JE, Chen W, Teegarden BR, Xiong Y, et al. (2009) APD791, 3-methoxy- N-(3-(1-methyl-1H-pyrazol-5-yl)-4-(2-morpholinoethoxy)phenyl)benzamide, a novel 5-hydroxytryptamine 2A receptor antagonist: Pharmacological profile, pharmacokinetics, platelet activity and vascular biology. J Pharmacol Exp Ther 331:96-103.
85. Clemetson KJ and Clemetson JM (2008) Platelet GPIb complex as a target for anti-thrombotic drug development. Thromb Haemost 99:473-479. (Pubitemid 351549283)
86. Löwenberg EC, Meijers JCM, and Levi M (2010) Platelet-vessel wall interaction in health and disease. Neth J Med 68:242-251.
87. Firbas C, Siller-Matula JM, and Jilma B (2010) Targeting von Willebrand factor and platelet glycoprotein Ib receptor. Expert Rev Cardiovasc Ther 8:1689-1701.
88. Sixma JJ, IJsseldijk MJW, Hindriks G, van Zanten GH, Gorecki M, Panet A, Garfinkel LI, and de Groot PG (1996) Adhesion of blood platelets is inhibited by VCL, a recombinant fragment (leucine504 to lysine728) of von Willebrand factor. Arterioscler Thromb Vasc Biol 16:64-71.
89. Kageyama S, Yamamoto H, Nakazawa H, Matsushita J, Kouyama T, Gonsho A, Ikeda Y, and Yoshimoto R (2002) Pharmacokinetics and pharmacodynamics of AJW200, a humanized monoclonal antibody to von Willebrand factor, in monkeys. Arterioscler Thromb Vasc Biol 22:187-192. (Pubitemid 34076252)
90. Van Bockstaele F, Holz JB, and Revets H (2009) The development of nanobodies for therapeutic applications. Curr Opin Investig Drugs 10:1212-1224.
91. Siller-Matula JM, Krumphuber J, and Jilma B (2010) Pharmacokinetic, pharmacodynamic and clinical profile of novel antiplatelet drugs targeting vascular diseases. Br J Pharmacol 159:502-517.
92. Gilbert JC, DeFeo-Fraulini T, Hutabarat RM, Horvath CJ, Merlino PG, Marsh HN, Healy JM, BouFakhreddine S, Holohan TV, and Schaub RG (2007) First-in-human evaluation of anti-von Willebrand factor therapeutic aptamer ARC1779 in healthy volunteers. Circulation 116:2678-2686. (Pubitemid 350291240)
93. Jilma-Stohlawetz P, Gorczyca ME, Jilma B, Siller-Matula J, Gilbert JC, and Knöbl P (2011) Inhibition of von Willebrand factor by ARC1779 in patients with acute thrombotic thrombocytopenic purpura. Thromb Haemost 105:545-552.
94. Nuyttens BP, Thijs T, Deckmyn H, and Broos K (2011) Platelet adhesion to collagen. Thromb Res 127 (Suppl 2):S26-S29.
95. White TC, Berny MA, Robinson DK, Yin H, DeGrado WF, Hanson SR, and McCarty OJ (2007) The leech product saratin is a potent inhibitor of platelet integrin a2ß1 and von Willebrand factor binding to collagen. FEBS J 274:1481-1491. (Pubitemid 46333741)
96. Shalito I, Kopyleva O, and Serebruany V (2009) Novel antiplatelet agents in development: Prasugrel, ticagrelor, and cangrelor and beyond. Am J Ther 16:451-458.
97. Combe S, Rosport K, and Kennedy A (2007) PR-15 a novel intravenous inhibitor of platelet adhesion: A phase I dose ascending pharmacokinetic, pharmacodynamic, and tolerance study. J Thromb Haemost 5 (Suppl 2):P-T-683 (abstract).
98. Jackson SP, Schoenwaelder SM, Goncalves I, Nesbitt WS, Yap CL, Wright CE, Kenche V, Anderson KE, Dopheide SM, Yuan Y, et al. (2005) PI 3-kinase p110ß: A new target for antithrombotic therapy. Nat Med 11:507-514. (Pubitemid 40685973)
99. Eisenreich A and Rauch U (2011) PI3K inhibitors in cardiovascular disease. Cardiovasc Ther 29:29-36.